| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2/3 data readout example | Phase 2/3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 2/3 data readout example | Phase 2/3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 2/3 data readout example | Phase 2/3 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Inhibrx Biosciences, Inc.$93.01
-10.84 (-10.44%)
D 37Pipeline Score Overvalued Biotech · Commercial
Market Cap
1.49 B
EPS
-8.39
P/E Ratio
-
Value Trade
30.61 M
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
25.22 M
Operating CF
-38.03 M
Total Assets
183.97 M
Total Liabilities
205.00 M
Equity
-21.04 M
D/E Ratio
12,345
-14.56 %
Week
-31.31 %
1 Month
25.91 %
3 Month
26.67 %
6 Month
500.95 %
5 Year
358.46 %
All Time
Cash Data
Cash Position
161.66 M
Monthly Burn
12.68 M
Runway
10.9 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
369.47 K
52 Week Range
12.68 - 155.29
% held by Insiders
25.92 %
% held by Institutions
77.08 %
Enterprise Value
1.51 B
Total Shares
14.68 M
Short %
37.09 %
Float Shares
9.29 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inhibrx Biosciences, Inc.
68Total events
7Upcoming
28Tier-1 (high impact)
2024 – 2027Coverage
Upcoming catalysts 7
Q4 2026
T1Topline Readout
PFS data from randomized Phase 2/3 trial in HNSCC in combination with pembrolizumab at ESMO 2026
2026-H2
T3Type B Meeting
Plan to meet with FDA in 2H 2026 to discuss first-line registrational trial in CRC and potential accelerated pathways for fourth-line CRC and refractory Ewing sarcoma
Event history 61
Q3 2026
◆Trial InitiationINBRX-106Trial
Phase 3 portion of HexAgon study to begin in Q3 2026
first-line Head and Neck Squamous Cell Carcinoma (HNSCC)source ↗
Jun 15, 2026
●BLA SubmissionINBRX-109Regulatory Filing
BLA submission for ozekibart in unresectable or metastatic conventional chondrosarcoma
conventional chondrosarcomasource ↗
Jun 15, 2026
▲FDA Filing AcceptedINBRX-109Regulatory Filing
FDA acceptance of BLA for ozekibart
conventional chondrosarcomasource ↗
May 11, 2026
◆Oral PresentationINBRX-106Presentation
Webcast presentation to provide interim results from randomized Phase 2 portion of HexAgon study
first-line HNSCCsource ↗
May 11, 2026
▲Interim AnalysisINBRX-106Trial
Interim Phase 2 data for INBRX-106 in combination with pembrolizumab vs pembrolizumab monotherapy in first-line HNSCC
first-line Head and Neck Squamous Cell Carcinoma (HNSCC)source ↗
May 2026
◆Interim AnalysisINBRX-106Trial
Updated interim data from randomized Phase 2 portion of HexAgon study for INBRX-106 in combination with pembrolizumab
Head and Neck Squamous Cell Carcinoma (HNSCC)source ↗
Apr 21, 2026
◆Oral PresentationINBRX-109Presentation
Webcast presentation to provide clinical update on ozekibart in combination with FOLFIRI in CRC
locally advanced or metastatic, unresectable colorectal cancersource ↗
Apr 21, 2026
▲Interim AnalysisINBRX-109Trial
Updated interim data from Phase 1/2 study of ozekibart + FOLFIRI in CRC
colorectal cancersource ↗
Apr 2026
●BLA SubmissionINBRX-109Regulatory Filing
BLA submitted to FDA for ozekibart in conventional chondrosarcoma
conventional chondrosarcomasource ↗
Q2 2026
◆Trial InitiationINBRX-106Trial
Initiate study in perioperative NSCLC later this quarter
non-small cell lung cancer (NSCLC) perioperative settingsource ↗
Q2 2026
◆FDA Feedback ReceivedINBRX-109FDA Meeting
FDA meeting to discuss accelerated approval for Ewing sarcoma and fourth-line colorectal cancer
Ewing sarcoma and fourth-line colorectal cancersource ↗
Drug Pipeline Intelligence
D37
Pipeline Score $76M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 51%
Micro Cap (rank 448 of 912)
Percentile RankInhibrx Biosciences, Inc. faces pipeline headwinds (37/100), with $277M risk-adjusted pipeline value, led by Pembrolizumab in Triple Negative Breast Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab Small molecule | Triple Negative Breast Cancer | Phase 2 | NCT06353997 | 10% | $108M | RECRUITING | 12 | - | - | Jun 1, 2029 | VERY_HIGH_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ozekibart | unresectable or metastatic conventional chondrosarcoma | — | 2026-06-15 | 52% reduction in the risk of disease progression or death compared to placebo; median PFS to 5.52 months versus 2.66 months for placebo; stratified Hazard Ratio HR 0.479 95% CI 0.33, 0.68 P 0.0001 Read More | Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma No filing review issues identified by FDA with PDUFA goal date set for Read More | |
ozekibart | unresectable or metastatic conventional chondrosarcoma | — | 2026-06-15 | 52% reduction in the risk of disease progression or death compared to placebo; median PFS to 5.52 months versus 2.66 months for placebo; stratified Hazard Ratio HR 0.479 95% CI 0.33, 0.68 P 0.0001 Read More | Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma No filing review issues identified by FDA with PDUFA goal date set for Read More | |
ozekibart | unresectable or metastatic conventional chondrosarcoma | — | 2026-06-15 | 52% reduction in the risk of disease progression or death compared to placebo; median PFS to 5.52 months versus 2.66 months for placebo; stratified Hazard Ratio HR 0.479 95% CI 0.33, 0.68 P 0.0001 Read More | Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma No filing review issues identified by FDA with PDUFA goal date set for Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INBX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INBX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INBXInhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma No filing review issues identified by FDA with PDUFA goal date set for
Inhibrx has announced that the FDA accepted its Biologics License Application for ozekibart, which targets conventional chondrosarcoma, a rare and aggressive bone cancer. The FDA has not identified any issues with the filing, setting a goal date for decision on April 14, 2027. If approved, ozekibart would be the first systemic treatment available for patients with unresectable or metastatic forms of this cancer. The application is backed by positive trial results, indicating significant benefits in progression-free survival compared to placebo.
Read more →INBXInhibrx Reports First Quarter 2026 Financial Results
Inhibrx Biosciences reported its financial results for Q1 2026, highlighting ongoing clinical trials for INBRX-106 and ozekibart. The company announced an increase in cash reserves and plans to release key trial data later in the year. However, it also reported a net loss and rising interest expenses.
Read more →INBX▼ -5%on this news· ran to -19% by day 1shared move
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Inhibrx Biosciences announced positive interim results from the Phase 2 HexAgon study evaluating INBRX-106 in combination with pembrolizumab for first-line HNSCC. The combination arm showed a 22.6% increase in confirmed responses compared to the control. The treatment demonstrated robust T-cell activation and a manageable safety profile. The company plans to initiate Phase 3 trials in Q3 2026.
Read more →INBX▲ +7.9%on this newsshared move
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
Inhibrx Biosciences will host a live webcast on May 11, 2026, to present interim results from the Phase 2 HexAgon study. This study evaluates the safety and efficacy of INBRX-106 in combination with pembrolizumab for first-line treatment of PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. The webcast will be accessible for 60 days after the event.
Read more →INBXInhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx Biosciences will host a live webcast on April 21, 2026, to provide clinical updates on ozekibart (INBRX-109) for colorectal cancer. This presentation will focus on the Phase 1/2 study evaluating ozekibart in combination with FOLFIRI. Ozekibart has previously received FDA designations for chondrosarcoma and has shown significant efficacy in clinical trials.
Read more →INBXInhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Inhibrx has provided an update on its Phase 1/2 study of ozekibart (INBRX-109) for colorectal cancer, revealing a 20% objective response rate and a median progression-free survival of 5.5 months. The drug demonstrated a manageable safety profile, with common side effects being mild. Inhibrx plans to discuss further development with the FDA, including potential first-line trials.
Read more →INBX▼ -6.1%on this news
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Inhibrx Biosciences reported its financial results for Q4 and fiscal year 2025, highlighting a cash position of $124.2 million. The company is progressing with two clinical programs and plans to submit a Biologics License Application (BLA) to the FDA in early Q2 2026. However, there are inherent risks related to data accuracy and clinical trial advancements.
Read more →INBXInhibrx Announces Participation in Upcoming Scientific Conference
Inhibrx Biosciences, Inc. announced its participation in the ESMO Sarcoma and Rare Cancers Congress scheduled for March 12-14, 2026, in Lugano, Switzerland. The company will present a Phase 1 study on the DR5 Agonist Ozekibart combined with Irinotecan and Temozolomide for Ewing Sarcoma. The presentation will be accessible via a link on Inhibrx's investor website.
Read more →INBXInhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Inhibrx Biosciences provided updates on its INBRX-106 and ozekibart programs, highlighting progress in clinical trials for head and neck squamous cell carcinoma and non-small cell lung cancer. The company is nearing completion of patient enrollment in these trials and anticipates data maturity in 2026. Additionally, ozekibart's combination therapies have shown positive outcomes, with plans for FDA discussions regarding accelerated approval.
Read more →INBX▲ +6%on this news
Inhibrx Reports Third Quarter 2025 Financial Results
Inhibrx Biosciences reported its third-quarter financial results for 2025, highlighting positive topline outcomes from its ozekibart trial in chondrosarcoma. Following a significant corporate restructuring, the company now operates with two clinical programs. Inhibrx plans to submit a biologics license application to the FDA in the second quarter of 2026.
Read more →INBXInhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx Biosciences, Inc. announced its participation in several upcoming scientific conferences, including the Precision Oncology & Radmed Symposium and the Society for NeuroOncology Annual Meeting. The presentations will focus on the clinical data of their DR5 agonist, ozekibart, in various cancer types. These events highlight Inhibrx's commitment to advancing its clinical pipeline.
Read more →INBX▲ +102%on this news· ran to +172% by day 3
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Inhibrx Biosciences reported positive topline results from its ChonDRAgon study, showing that ozekibart significantly improves median progression-free survival in patients with advanced chondrosarcoma. The study met its primary endpoint, demonstrating a 52% reduction in disease progression risk. Additionally, promising updates were shared regarding expansion cohorts for colorectal cancer and Ewing sarcoma, indicating potential for broader application of ozekibart.
Read more →INBX▼ -16%on this news· ran to +57% by day 3shared move
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts Inhibrx Biosciences, Inc. (Nasdaq: INBX) ( Inhibrx or the Company ), a clinical-stage biopharmaceutical company focused on developing therapeutics...
Inhibrx Biosciences, Inc. is set to host a live webcast on October 23, 2025, to present topline results from its registrational trial of ozekibart (INBRX-109) in patients with unresectable chondrosarcoma. The company will also provide updates on ongoing expansion trials for ozekibart in combination therapies for colorectal cancer and Ewing sarcoma. This presentation marks a key milestone in the clinical development of Inhibrx's product pipeline, highlighting its focus on innovative cancer treatments.
Read more →INBXInhibrx Reports Second Quarter 2025 Financial Results
Inhibrx Biosciences, Inc. reported its financial results for Q2 2025, highlighting two ongoing clinical trials with anticipated data readouts within the year. The company, formed after a spin-off from its former parent, has a pipeline that includes ozekibart (INBRX-109) and INBRX-106. Despite a rise in revenue, significant operating losses were reported, reflecting the challenges faced in the biopharmaceutical sector.
Read more →INBXInhibrx Reports First Quarter 2025 Financial Results San Diego, CA
Inhibrx Biosciences, Inc. reported its first quarter financial results for 2025, showcasing an increased cash balance following a successful financing round. The company now oversees two clinical programs, with expected data readouts for chondrosarcoma and colorectal cancer within this year. Research and development expenses decreased significantly compared to the previous year, while total operating expenses were also reduced. However, Inhibrx reported a net loss of $43.3 million for the quarter, highlighting persistent financial challenges as it continues to develop its clinical pipeline.
Read more →INBXInhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Inhibrx Biosciences has announced the departure of co-founder Dr. Brendan Eckelman, who will start a new biotechnology company. Dr. Carlos Bais has been appointed as the new Chief Scientific Officer, while David Matly has been promoted to President. The company is optimistic about its future with these leadership changes as it continues to develop its clinical pipeline.
Read more →INBXInhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results San Diego, CA
Inhibrx Biosciences, Inc. has reported its financial results for the fourth quarter and fiscal year 2024, highlighting a net loss of $47.9 million for the fourth quarter. The company has completed a significant loan agreement and increased its cash holdings to $230.5 million. Interim data from the Phase 1 trial of ozekibart indicated promising efficacy for treating advanced colorectal adenocarcinoma, with further expansion of clinical trials planned. The increase in general and administrative expenses was largely due to costs associated with the company's recent spin-off.
Read more →INBXInhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Inhibrx Biosciences announced preliminary data from its Phase 1 trial of ozekibart (INBRX-109) for advanced colorectal cancer. The trial showed one complete response and three partial responses among patients. Despite a high incidence of treatment-emergent adverse events, the company is encouraged by the results and plans to expand the trial cohort for further validation.
Read more →INBX▲ +5.2%on this newsshared move
Document Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Inhibrx Biosciences announced preliminary efficacy and safety results from a Phase 1 trial of ozekibart (INBRX-109) for treating advanced colorectal cancer. Among the 10 patients assessed, there were one complete response and three partial responses, with nearly half showing durable disease control for 180 days. Despite the promising results, treatment-emergent adverse events were common, affecting over 84% of patients, with about 30% experiencing more severe grade 3 events. The company is moving forward with an expansion cohort to further validate these findings.
Read more →INBX▼ -6.6%on this news
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
Inhibrx Biosciences has entered into a loan agreement with Oxford Finance, securing a five-year term loan facility of up to $150 million. This funding will provide strategic flexibility as the company anticipates key data readouts for its clinical programs, INBRX-109 and INBRX-106, later this year. The initial loan of $100 million has already been funded, with an option for an additional $50 million.
Read more →INBXDocument Inhibrx Biosciences Announces Loan Agreement with Oxford Finance San Diego, CA
Inhibrx Biosciences has announced a significant loan agreement with Oxford Finance, providing up to $150 million in a five-year term loan facility. This funding aims to enhance Inhibrx's strategic options as they prepare for important data readouts for their clinical programs INBRX-109 and INBRX-106. Both programs show potential based on previous clinical results, highlighting a positive outlook for the company's future developments. The initial funding of $100 million has been secured, with an option for an additional $50 million contingent on lender approval.
Read more →INBX▼ -7.2%on this news
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results San Diego, CA
Inhibrx Biosciences reported its financial results for the third quarter of 2024, revealing a net loss of $43.9 million. The company has $196.3 million in cash and is focused on its clinical trials for ozekibart (INBRX-109) and INBRX-106, with data readouts expected within the next year. However, despite a decrease in total revenue, operational costs have remained a concern with increased R&D spending.
Read more →INBXInhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation Inhibrx Biosciences, Inc. (Nasdaq: INBX) ( Inhibrx or the Company ), a biopharmaceutical company with two programs in ongoing clinical trials and a ...
Inhibrx Biosciences secured a legal victory against I-Mab Biopharma in a trade secrets case, with the jury rejecting all allegations against the company. The ruling affirms Inhibrx’s commitment to ethical standards in scientific research and its independent development processes. CEO Mark Lappe expressed gratitude for the support received and highlighted the company's renewed dedication to developing therapeutic solutions. The decision enables Inhibrx to concentrate on its mission of delivering innovative treatments to patients.
Read more →INBXInhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights San Diego, CA
Inhibrx Biosciences reported its financial results for the second quarter of 2024, showcasing a substantial net income of $1.9 billion, a significant improvement from a net loss of $47.1 million in Q2 2023. The company, post-spin-off from its former parent, retains a strong cash position of $226.9 million. Notably, while operational expenses have increased significantly, particularly in research and development and general administration, Inhibrx is focused on its clinical programs, INBRX-106 and ozekibart (INBRX-109).
Read more →INBXTABLE OF CONTENTS INHIBRX BIOSCIENCES, INC. 11025 N. TORREY PINES ROAD, SUITE 140 LA JOLLA, CALIFORNIA 92037
Inhibrx, Inc. has announced that its spin-off, Inhibrx Biosciences, Inc. (referred to as SpinCo), will become effective on May 29, 2024. SpinCo will focus on developing its pipeline of novel biologic therapeutic candidates, including INBRX-105, INBRX-106, and INBRX-109. Stockholders of Inhibrx, Inc. will receive shares of SpinCo on a pro-rata basis without needing to take action. The Distribution is contingent upon the satisfaction of certain conditions related to the merger agreement with Sanofi S.A.
Read more →Competitive Position
How INBX ranks across every disease it competes inCompetitive Position is a premium feature
See how INBX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial